Halozyme Therapeutics stock upgraded to Buy Candidate.

The Halozyme Therapeutics stock price gained 0.505% on the last trading day (Tuesday, 13th Jun 2023), rising from $33.68 to $33.85. During the last trading day the stock fluctuated 2.02% from a day low at $33.44 to a day high of $34.12. The price has been going up and down for this period, and there has been a 3.04% gain for the last 2 weeks. Volume fell on the last day by -21 thousand shares and in total, 810 thousand shares were bought and sold for approximately $27.42 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

Leerink Partners is very positive about HALO and gave it a "" rating on Jan 11, 2023. The price target was set to 61.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.Given the current short-term trend, the stock is expected to fall -10.48% during the next 3 months and, with a 90% probability hold a price between $25.54 and $33.66 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

The Halozyme Therapeutics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $33.92. On a fall, the stock will find some support from the long-term average at approximately $33.03. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Monday, May 08, 2023, and so far it has risen 11.79%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Halozyme Therapeutics finds support from accumulated volume at $33.68 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved $0.675 (2.02%) between high and low. For the last week, the stock has had daily average volatility of 2.46%.

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy candidate.